Publications by authors named "A Omlin"
Article Synopsis
- * Experts in the field gathered to discuss and improve the language surrounding this disease to make it less intimidating.
- * The goal is to establish a clearer and more accurate way to define the nomenclature related to advanced prostate cancer for better patient understanding.
Article Synopsis
- Innovations in advanced prostate cancer have improved outcomes, but there's still a lack of high-level evidence in clinical management, prompting the 2024 Advanced Prostate Cancer Consensus Conference to survey experts for insights.
- A panel of 120 international experts developed and voted on 183 consensus questions through a web-based survey prior to the conference, defining consensus as ≥75% agreement.
- The voting results highlight areas of agreement and disagreement that can guide clinical decisions and future research, with a focus on individualizing treatment based on patient characteristics and encouraging participation in clinical trials.
Article Synopsis
- The study focuses on improving follow-up care for patients with testicular cancer to detect relapses early by analyzing different imaging methods used for relapse detection in a large cohort of patients (1175 enrolled) from the Swiss Austrian German Testicular Cancer Cohort Study.
- Key findings included that 76% of analyzed patients had stage I disease, with a high 5-year relapse-free survival rate of 90.1%. Cross-sectional imaging of the abdomen was found to be the most effective method for detecting relapses, especially abdominal CT scans.
- The researchers proposed updated follow-up schedules emphasizing abdominal imaging while reducing reliance on chest X-rays, aiming to guide clinicians in future patient management strategies.
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study.
Prostate Cancer Prostatic Dis
August 2024
Background: KEYNOTE-199 (NCT02787005) is a multicohort phase 2 study evaluating pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC). Results from cohorts 4 (C4) and 5 (C5) are presented.
Methods: Eligible patients had not received chemotherapy for mCRPC and had responded to enzalutamide prior to developing resistance as defined by Prostate Cancer Clinical Trials Working Group 3 guidelines.
Although intermittent androgen deprivation therapy was often recommended for metastatic hormone-sensitive cancer therapy in the past, we do not know whether its use can be extrapolated to combination therapy. Trials evaluating intermittent therapy are necessary as this strategy could improve patient quality of life and reduce adverse events and costs.
View Article and Find Full Text PDF